Recipharm, the contract development and manufacturing organisation (CDMO), has partnered with Hadasit Medical Research Services and Development to offer combined clinical, biological and chemical services.
Located in Israel, Hadasit, a wholly owned subsidiary of Hadassah Medical Organisation (HMO), offers a variety of research, development and consulting services to customers, primarily in the Middle East.
With its unique access to HMO’s expert clinicians and researchers, the company provides clinical-oriented R&D services that can assist customers from the point of early preclinical development up to regulatory approval, saving valuable time and money.
Recipharm’s facility in Israel has partnered with the firm as part of its growth plans in the market and to enable a more seamless customer experience as pharmaceutical products progress through clinical phases. Recipharm established in Israel in 2015 and since then the business has grown to serve more than 50 customers, primarily in Israel and the USA.
Hadasit brings a number of specialist services to the partnership, including in vitro analysis in various models, access to and analysis of human samples, in vivo models for multiple medical conditions, input regarding medical indications and the conducting of clinical trials at all phases.